Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRamalingam, Suresh S-
dc.contributor.authorVansteenkiste, Johan-
dc.contributor.authorPlanchard, David-
dc.contributor.authorCho, Byoung Chul-
dc.contributor.authorGray, Jhanelle E-
dc.contributor.authorOhe, Yuichiro-
dc.contributor.authorZhou, Caicun-
dc.contributor.authorReungwetwattana, Thanyanan-
dc.contributor.authorCheng, Ying-
dc.contributor.authorChewaskulyong, Busyamas-
dc.contributor.authorShah, Riyaz-
dc.contributor.authorCobo, Manuel-
dc.contributor.authorLee, Ki Hyeong-
dc.contributor.authorCheema, Parneet-
dc.contributor.authorTiseo, Marcello-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorLin, Meng-Chih-
dc.contributor.authorImamura, Fumio-
dc.contributor.authorKurata, Takayasu-
dc.contributor.authorTodd, Alexander-
dc.contributor.authorHodge, Rachel-
dc.contributor.authorSaggese, Matilde-
dc.contributor.authorRukazenkov, Yuri-
dc.contributor.authorSoria, Jean-Charles-
dc.identifier.citationThe New England Journal of Medicine 2020; 382(1): 41-50-
dc.description.abstractOsimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). The trial showed longer progression-free survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46). Data from the final analysis of overall survival have not been reported. In this trial, we randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR mutation (exon 19 deletion or L858R allele) in a 1:1 ratio to receive either osimertinib (80 mg once daily) or one of two other EGFR-TKIs (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily, with patients receiving these drugs combined in a single comparator group). Overall survival was a secondary end point. The median overall survival was 38.6 months (95% confidence interval [CI], 34.5 to 41.8) in the osimertinib group and 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (hazard ratio for death, 0.80; 95.05% CI, 0.64 to 1.00; P = 0.046). At 3 years, 79 of 279 patients (28%) in the osimertinib group and 26 of 277 (9%) in the comparator group were continuing to receive a trial regimen; the median exposure was 20.7 months and 11.5 months, respectively. Adverse events of grade 3 or higher were reported in 42% of the patients in the osimertinib group and in 47% of those in the comparator group. Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA number, NCT02296125.).-
dc.titleOverall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.-
dc.typeJournal Article-
dc.identifier.journaltitleThe New England Journal of Medicine-
dc.identifier.affiliationthe Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium (J.V.); the Thoracic Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Franceen
dc.identifier.affiliationPulmonary Hospital of Tongji University, Shanghai, Chinaen
dc.identifier.affiliationEarly Oncology Research and Development, AstraZeneca, Gaithersburg, MDen
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwanen
dc.identifier.affiliationKent Oncology Centre, Maidstone Hospital, and Tunbridge Wells NHS Trust, Maidstone, United Kingdomen
dc.identifier.affiliationLate Oncology Statistics and Oncology Research and Development , AstraZeneca, Cambridge, United Kingdomen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationJilin Provincial Cancer Hospital, Changchun,Chinaen
dc.identifier.affiliationWinship Cancer Institute, Emory University School of Medicine, Atlantaen
dc.identifier.affiliationUniversity Paris Sud, Orsay, Franceen
dc.identifier.affiliationDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Koreaen
dc.identifier.affiliationDivision of Medical Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju, South Koreaen
dc.identifier.affiliationDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLen
dc.identifier.affiliationDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japanen
dc.identifier.affiliationDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japanen
dc.identifier.affiliationDepartment of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japanen
dc.identifier.affiliationHospital Regional Universitario Málaga, Instituto de Investigación Biomédica de Málaga, Malaga, Spainen
dc.identifier.affiliationWilliam Osler Health System, University of Toronto, Torontoen
dc.identifier.affiliationDepartment of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italyen
dc.identifier.affiliationFaculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailanden
dc.identifier.affiliationOncology Unit, Department of Medicine, Chiang Mai University, Chiang Mai, Thailanden
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 15, 2021

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.